These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 25670505)

  • 1. Patterns in spontaneous adverse event reporting among branded and generic antiepileptic drugs.
    Bohn J; Kortepeter C; Muñoz M; Simms K; Montenegro S; Dal Pan G
    Clin Pharmacol Ther; 2015 May; 97(5):508-17. PubMed ID: 25670505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).
    Rahman MM; Alatawi Y; Cheng N; Qian J; Plotkina AV; Peissig PL; Berg RL; Page D; Hansen RA
    Epilepsy Res; 2017 Sep; 135():71-78. PubMed ID: 28641219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methodological Considerations for Comparison of Brand Versus Generic Versus Authorized Generic Adverse Event Reports in the US Food and Drug Administration Adverse Event Reporting System (FAERS).
    Rahman MM; Alatawi Y; Cheng N; Qian J; Peissig PL; Berg RL; Page DC; Hansen RA
    Clin Drug Investig; 2017 Dec; 37(12):1143-1152. PubMed ID: 28933038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in Adverse Event Reporting Rates of Therapeutic Failure Between Two Once-daily Extended-release Methylphenidate Medications in Canada: Analysis of Spontaneous Adverse Event Reporting Databases.
    Park-Wyllie L; van Stralen J; Castillon G; Sherman SE; Almagor D
    Clin Ther; 2017 Oct; 39(10):2006-2023. PubMed ID: 28988700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brand vs generic adverse event reporting patterns: An authorized generic-controlled evaluation of cardiovascular medications.
    Alatawi Y; Rahman MM; Cheng N; Qian J; Peissig PL; Berg RL; Page CD; Hansen RA
    J Clin Pharm Ther; 2018 Jun; 43(3):327-335. PubMed ID: 29092097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Algorithm to Identify Generic Drugs in the FDA Adverse Event Reporting System.
    Iyer G; Marimuthu SP; Segal JB; Singh S
    Drug Saf; 2017 Sep; 40(9):799-808. PubMed ID: 28593504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the completeness and accuracy of MedWatch data.
    Getz KA; Stergiopoulos S; Kaitin KI
    Am J Ther; 2014; 21(6):442-6. PubMed ID: 23011177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
    Welch HK; Kellum JA; Kane-Gill SL
    Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Active and passive surveillance of enoxaparin generics: a case study relevant to biosimilars.
    Grampp G; Bonafede M; Felix T; Li E; Malecki M; Sprafka JM
    Expert Opin Drug Saf; 2015 Mar; 14(3):349-60. PubMed ID: 25557261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality and adverse events with brand and generic clopidogrel in the US Food and Drug Administration Adverse Event Reporting System.
    Serebruany VL; Hall TS; Atar D; Agewall S; Hyun Kim M; Geudelin B; Lomakin N; Marciniak TA
    Eur Heart J Cardiovasc Pharmacother; 2019 Oct; 5(4):210-215. PubMed ID: 30192939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The rise of the generic drug market and its implications for dermatology.
    Bhosle M; Balkrishnan R; Dewan T; Yelverton CB; Feldman SR
    J Dermatolog Treat; 2005; 16(5-6):295-8. PubMed ID: 16428148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lower Proportion of Spontaneous Adverse Event Reports for Generic Drugs by Comparison With Original Branded Drugs at the Postmarket Stage in Japan.
    Takami A; Hirata K; Ishiguro C; Hanaoka H; Uyama Y
    Clin Pharmacol Ther; 2019 Jun; 105(6):1471-1476. PubMed ID: 30588617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy.
    Makus KG; McCormick J
    Clin Ther; 2007 Feb; 29(2):334-41. PubMed ID: 17472825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mining association patterns of drug-interactions using post marketing FDA's spontaneous reporting data.
    Ibrahim H; Saad A; Abdo A; Sharaf Eldin A
    J Biomed Inform; 2016 Apr; 60():294-308. PubMed ID: 26903152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Adverse drug reactions reporting is helping "non substituable" prescription!].
    Jacquot J; Bagheri H; Montastruc JL
    Therapie; 2014; 69(3):259-61. PubMed ID: 24927508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjunctive topiramate enhances the risk of hypothermia associated with valproic acid therapy.
    Knudsen JF; Sokol GH; Flowers CM
    J Clin Pharm Ther; 2008 Oct; 33(5):513-9. PubMed ID: 18834366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prescription for fairness: a new approach to tort liability of brand-name and generic drug manufacturers.
    Rostron A
    Duke Law J; 2011 Feb; 60(5):1123-91. PubMed ID: 21365961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prescribing generic antiepileptic drugs: Issues and concerns for nurse practitioners.
    Barrett MW
    J Am Acad Nurse Pract; 2010 Jun; 22(6):300-4. PubMed ID: 20536627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does public perception bias lead to more frequent reporting of adverse events: branded vs generic drugs.
    Qian J; Mishuk AU; Hansen RA
    Expert Opin Drug Saf; 2018 Aug; 17(8):753-756. PubMed ID: 30052091
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.